Pfizer shot protects against MIS-C, CDC study finds

Two doses of Pfizer-BioNTech's COVID-19 vaccine was 91 percent effective at preventing multisystem inflammatory syndrome in children, or MIS-C, a rare but serious condition tied to COVID-19, according to the CDC's Jan. 7 Morbidity and Mortality Weekly Report

While evidence showing high vaccine effectiveness against severe COVID-19 among children and adolescents has been well documented, the shot's effectiveness against MIS-C has been less explored, the report said. 

The study involved 283 inpatients aged 12 to 18 across 24 U.S. pediatric hospitals from July to Dec. 9, 2021 — a period in which delta which was the dominant circulating strain and before children younger than 12 were eligible for the vaccine. A total of 102 of the patients had MIS-C, and a control group of 181 patients either tested negative for COVID-19 or did not have symptoms. 

Most patients with MIS-C, 95 percent, were unvaccinated, the findings showed. Additionally, no fully vaccinated patient with MIS-C needed respiratory or cardiovascular life support, compared to 39 percent of unvaccinated MIS-C patients who did. 

"Receipt of two doses of the Pfizer-BioNTech vaccine is associated with a high level of protection against MIS-C in persons aged 12-18, highlighting the importance of vaccination among all eligible children," researchers said. 

Pfizer's vaccine is the only one authorized for use among people under the age of 18. Children 5 and older are eligible for primary vaccination, and boosters are recommended for those 12 and older. 


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Articles We Think You'll Like